Teva and Savient Launch TEV-TROPIN for Pediatric Growth Hormone Defici

    Business Editors

    JERUSALEM--(BUSINESS WIRE)--Feb. 11, 2005--Teva Pharmaceuticals Industries Ltd. (Nasdaq: TEVA) and Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) have announced the U.S. launch of TEV-TROPIN(TM) (somatropin (rDNA origin) for injection), a growth hormone product for the treatment of children with short stature due to growth hormone deficiency. This product was clinically tested and FDA-approved for growth hormone deficiency (GHD), and is manufactured by Savient using recombinant DNA (rDNA) technology.
    Teva has begun offering TEV-TROPIN(TM) to pediatric endocrinologists through its fully owned GATE Pharmaceuticals sales force. To maximize value to physicians and patients and to support optimal outcomes, Teva is providing a comprehensive patient support program known as Growth Solutions(SM), including a patient enrollment program and call center located within Teva Neuroscience, Inc. Growth Solutions(SM) utilizes world-class customer relationship management technology that is also currently being used to support Copaxone(R), Teva's successful multiple sclerosis drug, and its respective Shared Solutions(TM) patient support program. Patients can be enrolled in Growth Solutions(SM) by calling the toll-free number: (866) 838-8767.
    "We welcome any new drug that makes treatment for growth hormone deficiency more accessible for patients and their families," said Patricia Costa, Executive Director of the Human Growth Foundation. "TEV-TROPIN(TM) in concert with the Growth Solutions(SM) support program bring more choice and clarity to these families."
    Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva's sales are in North America and Europe.

    Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products (so called "authorized generics") or successfully extend the exclusivity period of their branded products, the effects of competition on Copaxone(R) sales, including potential competition from the launch of Tysabri(R) Teva's ability to rapidly integrate the operations of acquired businesses, including its acquisition of Sicor Inc., regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to completion of appellate litigation, including that relating to Neurontin, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations outside the United States that may be adversely affected by terrorism or major hostilities, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

--30--AC/ny*

CONTACT: Teva Pharmaceutical Industries Ltd. Dan Suesskind, (011) 972-2-589-2840 or Teva North America George Barrett, 215-591-3030 or Teva Pharmaceutical Industries Ltd. Dorit Meltzer, (011) 972-3-926-7554

KEYWORD: ISRAEL INTERNATIONAL AFRICA/MIDDLE EAST INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL MEDICAL DEVICES BIOTECHNOLOGY PRODUCT SOURCE: Teva Pharmaceuticals Industries Ltd.

Copyright Business Wire 2005